Article
Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2021
Börcsök Judit, Diossy Miklos, Sztupinszki Zsofia, Prosz Aurel, Tisza Viktoria, Spisak Sandor, Rusz Orsolya, Stormoen Dag R, Pappot Helle, Csabai Istvan, Brunak Søren, Mouw Kent W, Szallasi Zoltan
Abstract excerpt
PURPOSE: Poly (ADP ribose)-polymerase (PARP) inhibitors are approved for use in breast, ovarian, prostate, and pancreatic cancers, which are the solid tumor types that most frequently have alterations in key homologous recombination (HR) genes, such as BRCA1/2. However, the frequency of HR deficiency (HRD) in other solid tumor types, including bladder cancer, is less well characterized. EXPERIMENTAL DESIGN:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.